专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07478008B2 System and method for the non-destructive assessment of the quantitative spatial distribution of components of a medical device 有权
标题翻译：医疗器械组件定量空间分布的无损评估系统和方法
公开(公告)号：US07478008B2
公开(公告)日：2009-01-13
申请号：US11780342
申请日：2007-07-19
申请人： Karin Maria Balss , Gerard Llanos , Cynthia Anne Maryanoff , George Papandreou , Vladimir Veselov
发明人： Karin Maria Balss , Gerard Llanos , Cynthia Anne Maryanoff , George Papandreou , Vladimir Veselov
IPC分类号： G06F15/00
CPC分类号： G01N21/65 , G01N21/95 , G06F19/00 , G06F19/703 , G06F19/707 , G16H40/20
摘要： A method and system for the non-destructive analysis of medical devices uses a confocal Raman microscope and other non-destructive analytical tools to assess the spatial distribution of components of an object such as the distribution of an active pharmaceutical ingredient (API) within a polymer matrix. In a preferred embodiment, confocal Raman spectroscopy was used to differentiate each component found in the sirolimus-eluting coronary stent. The unique spectral features identified for each component were then used to develop three separate calibration curves to describe the solid phase distribution found on drug-polymer coated stents. The calibration curves were obtained by analyzing confocal Raman spectral depth profiles from a set of 16 unique formulations of drug-polymer coatings sprayed onto stents and planar substrates.
摘要翻译：用于医疗装置的非破坏性分析的方法和系统使用共焦拉曼显微镜和其他非破坏性分析工具来评估物体的组分的空间分布，例如聚合物内的活性药物成分（API）的分布矩阵。在优选实施方案中，使用共焦拉曼光谱法来区分在西罗莫司洗脱冠状动脉支架中发现的每种成分。然后使用为每个组分鉴定的独特光谱特征来开发三个单独的校准曲线来描述在药物聚合物涂覆的支架上发现的固相分布。校准曲线通过从喷雾在支架和平面基底上的16组独特的药物 - 聚合物涂层制剂的分析共聚焦拉曼光谱深度分布图获得。

2. 发明申请

US20080228428A1 SYSTEM AND METHOD FOR THE NON-DESTRUCTIVE ASSESSMENT OF THE QUANTITATIVE SPATIAL DISTRIBUTION OF COMPONENTS OF A MEDICAL DEVICE 有权
标题翻译：医疗器械组件定量空间分配的非破坏性评估系统与方法
公开(公告)号：US20080228428A1
公开(公告)日：2008-09-18
申请号：US11780342
申请日：2007-07-19
申请人： Karin Maria Balss , Gerard Llanos , Cynthia Maryanoff , George Papandreou , Vladimir Veselov
发明人： Karin Maria Balss , Gerard Llanos , Cynthia Maryanoff , George Papandreou , Vladimir Veselov
IPC分类号： G06F15/00
CPC分类号： G01N21/65 , G01N21/95 , G06F19/00 , G06F19/703 , G06F19/707 , G16H40/20
摘要： A method and system for the non-destructive analysis of medical devices uses a confocal Raman microscope and other non-destructive analytical tools to assess the spatial distribution of components of an object such as the distribution of an active pharmaceutical ingredient (API) within a polymer matrix. In a preferred embodiment, confocal Raman spectroscopy was used to differentiate each component found in the sirolimus-eluting coronary stent. The unique spectral features identified for each component were then used to develop three separate calibration curves to describe the solid phase distribution found on drug-polymer coated stents. The calibration curves were obtained by analyzing confocal Raman spectral depth profiles from a set of 16 unique formulations of drug-polymer coatings sprayed onto stents and planar substrates.
摘要翻译：用于医疗装置的非破坏性分析的方法和系统使用共焦拉曼显微镜和其他非破坏性分析工具来评估物体的组分的空间分布，例如聚合物中活性药物成分（API）的分布矩阵。在优选实施方案中，使用共焦拉曼光谱法来区分在西罗莫司洗脱冠状动脉支架中发现的每种成分。然后使用为每个组分鉴定的独特光谱特征来开发三个单独的校准曲线来描述在药物聚合物涂覆的支架上发现的固相分布。校准曲线通过从喷雾在支架和平面基底上的16组独特的药物 - 聚合物涂层制剂的分析共聚焦拉曼光谱深度分布图获得。

3. 发明申请

US20050004663A1 Heparin barrier coating for controlled drug release 有权
标题翻译：肝素屏障涂层用于受控药物释放
公开(公告)号：US20050004663A1
公开(公告)日：2005-01-06
申请号：US10872990
申请日：2004-06-21
申请人： Gerard Llanos , Pallassana Narayanan , George Papandreou
发明人： Gerard Llanos , Pallassana Narayanan , George Papandreou
IPC分类号： A61B17/00 , A61B17/04 , A61B17/06 , A61B17/064 , A61B17/11 , A61B17/115 , A61B17/54 , A61F2/00 , A61F2/06 , A61K31/436 , A61K31/727 , A61K45/06 , A61L27/34 , A61L31/10 , A61L31/16
CPC分类号： A61B17/0644 , A61B17/00491 , A61B17/0469 , A61B17/11 , A61B17/115 , A61B2017/06028 , A61F2/064 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61F2310/0097 , A61K31/436 , A61K31/727 , A61K45/06 , A61L27/34 , A61L31/10 , A61L31/16 , A61K2300/00 , C08L27/12
摘要： Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations as well as other therapeutic agents may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices. In each of these instances, antioxidants are utilized to prolong product integrity.
摘要翻译：可以涂覆医疗装置，特别是可植入医疗装置，以最小化或基本上消除生物体对将生物体引入医疗装置的反应。医疗装置可以涂覆任何数量的生物相容性材料。治疗药物，药剂或化合物可以与生物相容性材料混合并固定在医疗装置的至少一部分上。这些治疗药物，药剂或化合物还可以进一步减少生物体对将生物体引入医疗装置的反应。此外，这些治疗药物，药剂和/或化合物可用于促进愈合，包括血块的形成。药物，药剂和/或化合物也可用于治疗特定疾病，包括易损斑块。治疗剂也可以递送到疾病部位的区域。在区域递送中，液体制剂可能是期望的，以增加特定药物的功效和递送能力。此外，可以修改装置以促进内皮化。可以使用各种材料和涂覆方法来将药物，试剂或化合物维持在医疗装置上，直到输送和定位。此外，可以修改用于递送可植入医疗装置的装置，以减少在展开期间损害可植入医疗装置的可能性。医疗器械包括支架，移植物，吻合装置，血管周围包裹物，缝线和钉。此外，可以使用各种聚合物组合以及其它治疗剂来控制来自可植入医疗装置的治疗药物，药剂和/或化合物的洗脱速率。在每种情况下，使用抗氧化剂来延长产品的完整性。

4. 发明申请

US20080247320A1 NETWORK SERVICE OPERATIONAL STATUS MONITORING 有权
标题翻译：网络服务运行状态监控
公开(公告)号：US20080247320A1
公开(公告)日：2008-10-09
申请号：US11696970
申请日：2007-04-05
申请人： ADRIAN GRAH , George Papandreou , Lyle Strub
发明人： ADRIAN GRAH , George Papandreou , Lyle Strub
IPC分类号： G06F11/00
CPC分类号： H04L41/5012 , H04L67/02
摘要： Network service operational status monitoring methods and apparatus are disclosed. Responsive to a service status request associated with a network service, an operational status of the network service is determined by an intermediary between a service status requester and the network service. The operational status is a service-specific operational status of the network service in some embodiments. Operational status may be determined through a multi-level procedure in which subsequent levels after a first level of the multi-level procedure are or are not performed depending on a result of a preceding level of the procedure. A multi-level procedure may involve a service connectivity check and a service operational check, for instance.
摘要翻译：公开了网络服务运行状态监控方法和装置。响应于与网络服务相关联的服务状态请求，网络服务的操作状态由服务状态请求者和网络服务之间的中介确定。在一些实施例中，操作状态是网络服务的服务特定操作状态。可以通过多级程序来确定操作状态，其中根据过程的先前水平的结果，执行多级过程的第一级别之后的后续级别是否被执行。例如，多级过程可以涉及服务连接性检查和服务操作检查。

5. 发明授权

US5663355A Monosaccharide analog-based glycosidase inhbitors 失效
标题翻译：单糖类似物糖苷酶抑制剂
公开(公告)号：US5663355A
公开(公告)日：1997-09-02
申请号：US374812
申请日：1995-01-19
申请人： Bruce Ganem , Michael K. Tong , George Papandreou
发明人： Bruce Ganem , Michael K. Tong , George Papandreou
IPC分类号： C07H5/06 , C07H11/00 , C07H15/12 , C07H15/18 , C07H15/203 , C07H19/04 , C07D211/54 , C07D207/273 , C07D211/42
CPC分类号： C07H5/06 , C07H11/00 , C07H15/12 , C07H15/18 , C07H15/203 , C07H19/04
摘要： Broad spectrum glycosidase inhibitors are produced from monosaccharide lactams by conversion to amidines, amidrazones or amidoximes. The inhibitors have the general formula: ##STR1## wherein the N and C are joined as part of a monosaccharide azaanalog ring and wherein --NRQ, together with the nitrogen and carbon atoms, form a chemical group selected from amidines, amidrazones, and amidoximes.
摘要翻译：广谱糖苷酶抑制剂由单糖内酰胺通过转化成脒，氨基腙或酰胺肟而产生。抑制剂具有以下通式：其中N和C作为单糖azaanalog环的一部分连接，其中-NRQ与氮和碳原子一起形成选自脒，氨基腙和酰胺肟的化学基团。

6. 发明授权

US5231185A Monosaccharide analog-based glycosidase inhibitors 失效
标题翻译：基于单糖类似物的糖苷酶抑制剂
公开(公告)号：US5231185A
公开(公告)日：1993-07-27
申请号：US734593
申请日：1991-07-23
申请人： Bruce Ganem , Michael K. Tong , George Papandreou
发明人： Bruce Ganem , Michael K. Tong , George Papandreou
IPC分类号： C07H5/06 , C07H11/00 , C07H15/12 , C07H15/18 , C07H15/203 , C07H19/04
CPC分类号： C07H5/06 , C07H11/00 , C07H15/12 , C07H15/18 , C07H15/203 , C07H19/04
摘要： Broad spectrum glycosidase inhibitors are produced from monosaccharide lactams by conversion to amidines, amidrazones, or amidoximes. The inhibitors have the general formula: ##STR1## wherein the N and C are joined as part of a monosaccharide azaanalog ring and wherein --NRQ, together with the nitrogen and carbon atoms, form a chemical group selected from amidines, amidrazones, and amidoximes.
摘要翻译：广谱糖苷酶抑制剂通过转化为脒，氨基腙或酰胺肟从单糖内酰胺产生。抑制剂具有以下通式：其中N和C作为单糖azaanalog环的一部分连接，其中-NRQ与氮和碳原子一起形成选自脒，氨基腙和酰胺肟的化学基团。

7. 发明申请

US20070294253A1 SECURE DOMAIN INFORMATION PROTECTION APPARATUS AND METHODS 审中-公开
标题翻译：安全域信息保护装置和方法
公开(公告)号：US20070294253A1
公开(公告)日：2007-12-20
申请号：US11467387
申请日：2006-08-25
申请人： Lyle Strub , Brad James Whitehead , George Papandreou
发明人： Lyle Strub , Brad James Whitehead , George Papandreou
IPC分类号： G06F17/30
CPC分类号： H04L63/102 , H04L63/0428 , H04L63/105 , H04L63/1458
摘要： Secure domain information protection apparatus and methods are disclosed. Service access information associated with access, by an external user that is outside a secure domain, to a service that is provided in the secure domain is processed to determine whether it includes sensitive information. If so, a protection action is performed on the service access information, on an entire service message or to one or more portions thereof, for example, to protect the sensitive information. A specification language and execution environment are also proposed to provide for high speed processing. Sensitive information detection criteria, protection actions, and possibly targets on which the protection actions are to be performed, may be identified in a data structure stored on a machine-readable medium.
摘要翻译：公开了安全域信息保护装置和方法。处理与由安全域外的外部用户访问相关联的服务访问信息到安全域中提供的服务，以确定其是否包含敏感信息。如果是，则对服务访问信息，整个服务消息或其一个或多个部分执行保护动作，例如以保护敏感信息。还提出了一种规范语言和执行环境来提供高速处理。可以在存储在机器可读介质上的数据结构中识别敏感信息检测标准，保护动作以及可执行保护动作的目标。

8. 发明授权

US08182527B2 Heparin barrier coating for controlled drug release 有权
标题翻译：肝素屏障涂层用于受控药物释放
公开(公告)号：US08182527B2
公开(公告)日：2012-05-22
申请号：US10872990
申请日：2004-06-21
申请人： Gerard H. Llanos , Pallassana V. Narayanan , George Papandreou
发明人： Gerard H. Llanos , Pallassana V. Narayanan , George Papandreou
IPC分类号： A61F2/06
CPC分类号： A61B17/0644 , A61B17/00491 , A61B17/0469 , A61B17/11 , A61B17/115 , A61B2017/06028 , A61F2/064 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61F2310/0097 , A61K31/436 , A61K31/727 , A61K45/06 , A61L27/34 , A61L31/10 , A61L31/16 , A61K2300/00 , C08L27/12
摘要： Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. In addition, various polymer combinations as well as other therapeutic agents may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.
摘要翻译：可以涂覆医疗装置，特别是可植入医疗装置，以最小化或基本上消除生物体对将生物体引入医疗装置的反应。医疗装置可以涂覆任何数量的生物相容性材料。治疗药物，药剂或化合物可以与生物相容性材料混合并固定在医疗装置的至少一部分上。此外，可以使用各种聚合物组合以及其它治疗剂来控制来自可植入医疗装置的治疗药物，药剂和/或化合物的洗脱速率。

9. 发明授权

US5434266A Monosaccharide analog-based glycosidase inhibitors 失效
标题翻译：基于单糖类似物的糖苷酶抑制剂
公开(公告)号：US5434266A
公开(公告)日：1995-07-18
申请号：US54885
申请日：1993-04-29
申请人： Bruce Ganem , Michael K. Tong , George Papandreou
发明人： Bruce Ganem , Michael K. Tong , George Papandreou
IPC分类号： C07H5/06 , C07H11/00 , C07H15/12 , C07H15/18 , C07H15/203 , C07H19/04 , C07D211/72 , C07D207/22
CPC分类号： C07H5/06 , C07H11/00 , C07H15/12 , C07H15/18 , C07H15/203 , C07H19/04
摘要： Broad spectrum glycosidase inhibitors are produced from monosaccharide lactams by conversion to amidines, amidrazones, or amidoximes. The inhibitors have the general formula: ##STR1## wherein the N and C are joined as part of a monosaccharide azaanalog ring and wherein --NRQ, together with the nitrogen and carbon atoms, form a chemical group selected from amidines, amidrazones, and amidoximes.
摘要翻译：广谱糖苷酶抑制剂通过转化为脒，氨基腙或酰胺肟从单糖内酰胺产生。抑制剂具有以下通式：其中N和C作为单糖azaanalog环的一部分连接，其中-NRQ与氮和碳原子一起形成选自脒，氨基腙和酰胺肟的化学基团。

10. 发明授权

US08239520B2 Network service operational status monitoring 有权
标题翻译：网络服务运行状态监控
公开(公告)号：US08239520B2
公开(公告)日：2012-08-07
申请号：US11696970
申请日：2007-04-05
申请人： Adrian Grah , George Papandreou , Lyle Strub
发明人： Adrian Grah , George Papandreou , Lyle Strub
IPC分类号： G06F15/173
CPC分类号： H04L41/5012 , H04L67/02
摘要： Network service operational status monitoring methods and apparatus are disclosed. Responsive to a service status request associated with a network service, an operational status of the network service is determined by an intermediary between a service status requester and the network service. The operational status is a service-specific operational status of the network service in some embodiments. Operational status may be determined through a multi-level procedure in which subsequent levels after a first level of the multi-level procedure are or are not performed depending on a result of a preceding level of the procedure. A multi-level procedure may involve a service connectivity check and a service operational check, for instance.
摘要翻译：公开了网络服务运行状态监控方法和装置。响应于与网络服务相关联的服务状态请求，网络服务的操作状态由服务状态请求者和网络服务之间的中介确定。在一些实施例中，操作状态是网络服务的服务特定操作状态。可以通过多级程序来确定操作状态，其中根据过程的先前水平的结果，执行多级过程的第一级别之后的后续级别是否被执行。例如，多级过程可以涉及服务连接性检查和服务操作检查。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式